19 results
8-K
EX-99.1
ZYME
Zymeworks Inc.
2 May 24
Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results
4:07pm
at the American Society of Clinical Oncology (ASCO) annual meeting submitted by our partner, Jazz Pharmaceuticals
Presentation of five abstracts at the American
8-K
EX-99.1
ZYME
Zymeworks Inc.
6 Mar 24
Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results
4:13pm
, in multiple HER2-expressing cancers.
In December 2023, response rates in the HERIZON-BTC-01 Asian subgroup cohort were presented at the European Society … of 15 months. The combination regimen was well tolerated with a manageable safety profile.
In January 2024 at the American Society of Clinical Oncology
8-K
EX-99.1
ZYME
Zymeworks Inc.
8 Feb 24
Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors
4:16pm
for the Biomarker section of the Journal for ImmunoTherapy of Cancer and co-chair of the Society for Immunotherapy of Cancer (SITC) regulatory committee
8-K
EX-99.1
088lxqfh wuz
4 Jan 24
Zymeworks Outlines Strategic Priorities and Outlook for 2024 and 2025
6:31am
8-K
EX-99.1
20man
7 Nov 23
Zymeworks Provides Corporate Update and Reports Third Quarter 2023 Financial Results
4:08pm
8-K
EX-99.1
pv366tos zc357r5115l
16 Oct 23
Zymeworks Announces New Director Nominee
4:45pm
8-K
EX-99.1
7unlt7 mv52
10 Aug 23
Zymeworks Provides Corporate Update and Reports Second Quarter 2023 Financial Results
4:08pm
8-K
6cg 7zr6i1628nyrmz
2 Jun 23
Other Events
7:48pm
8-K
EX-99.1
tsvy76jux36g8kpb
8 May 23
Zymeworks Provides Corporate Update and Reports First Quarter 2023 Financial Results
4:13pm
8-K
EX-99.1
bv19k4blfbkcnk yk
10 Apr 23
Zymeworks Announces Appointment of Derek J. Miller to its Board of Directors
4:46pm
DEF 14A
svct u80k
25 Nov 22
Definitive proxy
6:16am
10-Q
xsh7mndiroxe9bzt
8 Nov 22
Quarterly report
4:09pm
- Prev
- 1
- Next